Welcome   >  Are you afraid of...

Are you afraid of developing dementia in your 70s? A study shows you need to act now.

hypertension démence A new study suggests that people suffering from hypertension in middle age are at significant risk of developing a form of dementia when they’re older (20 years later).

It also shows, for the first time, that the earliest signs of damage to the brain can be detected by an MRI, even before dementia symptoms are apparent. “The neurological changes associated with hypertension are normally diagnosed when cognitive decline becomes evident or when conventional MRIs show clear signs of brain damage”, said study coordinator Giuseppe Lemboem>. “But in either case, it is often too late to stop the disease process”.

How can you prevent hypertension in order to lower your risk of dementia?

Nobody wants to one day fall victim to senile dementia. According to this study, immediately reducing your blood pressure will also lower your risk of vascular dementia which could develop within the space of several years or decades.

How can you do this? If you’re already suffering from hypertension, your doctor will no doubt have prescribed suitable medication, but there are a number of other measures which, provided they become habitual, can help you reduce your blood pressure quickly and durably. Some of these (which are also beneficial for people who are not yet hypertensive) are outlined below:

  • Maintain a healthy weight.
  • Get active: in a study of more than 6000 subjects aged 35-60, those who began walking more than 20 minutes a day reduced their hypertension by 30%.
  • Learn to manage day to day stress. The adrenalin secreted in situations of chronic stress raises blood pressure due to its vasoconstricting effect (narrowing of blood vessels).
  • Reduce salt consumption and increase that of potassium-rich foods. The ideal sodium:potassium ratio for optimal blood pressure is estimated to be 1:5 whereas that of Western diets may actually be 2:1. To get closer to the ideal, it’s advisable to restrict sodium consumption to 2300mg/day and to consume plenty of fruit and vegetables.

How about dietary supplements?

For those suffering from hypertension, there are two key supplements which have been extensively documented in the scientific literature:

Omega-3 fatty acid supplements (ADH and/or EPA). Scientific data (1-4) demonstrates unequivocally that omega-3 supplements reduce systolic pressure (by around 3.5 mmHg) and diastolic (by around 2.5 mmHg) in people with hypertension. On average, 900mg/day of EPA/DHA is sufficient to reduce blood pressure (ie 3 capsules of Super-Omega-3).

These supplements also have beneficial effects on several risk factors for stroke and other cardiovascular diseases: blood lipid levels, vascular function, inflammation, platelet function… These effects have been scientifically-recognised by the EFSA as have their benefits for blood pressure: the Agency’s independent scientific committee studied several meta-analyses before reaching their opinion (which can be accessed at ici et ici).

Co-enzyme Q10 supplements. Co-enzyme Q10 is relatively unknown yet it’s an antioxidant which the body produces itself and which has been shown in several clinical trials to be effective when used in combination with standard hypertension medication. Reductions in blood pressure have thus been recorded in individuals taking co-enzyme Q10 (almost 100mg/day, ie 3 capsules of Coenzyme Q10 30 mg) in several randomised clinical trials (5-8).

In terms of natural products, hawthorn leaf extracts (found in the supplement Tensix) are effective at optimising cardiovascular function (their use is recognised by ESCOP and the World Health Organisation) while the benefits of Bacopa monnieri extracts are well-established in terms of maintaining the cognitive system (9-14), as well as visual perception, attention and language (verbal understanding and vocabulary) and reducing impulsivity (15-16), improving concentration and reasoning (17), as well as alertness and speed of information-processing (18), associative memory (19), retention of new information (20) and even reducing the tendency to make mistakes (21-22).

How does hypertension lead to dementia?

It’s a process which has been studied for several years already but new mechanisms controlling its development continue to be discovered.

In hypertension, the blood exerts abnormally high pressure on the artery walls, making them fragile. Little by little, the diameter of the vessels which transport blood to the brain gets smaller as a result of thickening of the vascular wall, thus reducing the supply of nutrients and oxygen to cells in the cerebral hemisphere (23).

Over the long-term, this under-supply manifests in damage to the brain’s white matter: “in people with hypertension, we can see a deterioration in white matter fibres connecting areas of the brain involved in attention, emotions and memory” said Lorenzo Carnevale, the study’s lead author.

The majority of published studies report a link between raised blood pressure and poorer cognitive performance, even in young people. But it’s really after suffering from hypertension for several years that the dementia process starts to develop. In those unlucky enough to be affected, blood pressure starts to fall: what appears to be an improvement is in fact a sign that degenerative damage has affected the cells involved in regulating that pressure. The gradual decrease in blood pressure seen in dementia is in fact proportionate to the loss of neurons.

Individuals most at risk are those who develop hypertension before the age of 60 (24).

The article at the centre of this study

Lorenzo Carnevale, Valentina D’Angelosante, Alessandro Landolfi, Giovanni Grillea, Giulio Selvetella, Marianna Storto, Giuseppe Lembo, Daniela Carnevale. Brain MRI fiber-tracking reveals white matter alterations in hypertensive patients without damage at conventional neuroimaging. Cardiovascular Research, 2018; DOI :10.1093/cvr/cvy104


  1. Appel LJ, Miller ER 3rd, et al. Does supplementation of diet with 'fish oil' reduce blood pressure? A meta-analysis of controlled clinical trials. Arch Intern Med. 1993 Jun 28;153(12):1429-38.
  2. Howe PR. Can we recommend fish oil for hypertension?Clin Exp Pharmacol Physiol. 1995 Mar;22(3):199-203. Review.
  3. Geleijnse JM, Giltay EJ, et al. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens. 2002 Aug; 20(8):1493-9.
  4. Morris MC, Sacks F, Rosner B. Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation. 1993 Aug;88(2):523-33.
  5. Langsjoen H, Langsjoen P, et al. Usefulness of coenzyme Q10 in clinical cardiology: a long-term study.Mol Aspects Med. 1994;15 Suppl:s165-75.
  6. Singh RB, Niaz MA, et al. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. J Hum Hypertens.1999 Mar;13(3):203-8.
  7. Burke BE, Neuenschwander R, Olson RD. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension.South Med J. 2001 Nov;94(11):1112-7.
  8. Hodgson JM, Watts GF, et al. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes.Eur J Clin Nutr. 2002 Nov;56(11):1137-42.
  9. Downey, L.A.; Kean, J.; Nemeh, F.; Lau, A.; Poll, A.; Gregory, R.; Murray, M.; Rourke, J.; Patak, B.; Pase, M.; et al. An acute, double-blind, placebo-controlled crossover study of 320 mg and 640 mg doses of a special extract of Bacopa monnieri (CDRI 08) on sustained cognitive performance. Phytother. Res. 2013, 27, 1407–1413.
  10. Benson, S.; Downey, L.A.; Stough, C.; Wetherell, M.; Zangara, A.; Scholey, A. An acute, double-blind, placebo-controlled cross-over study of 320 mg and 640 mg doses of Bacopa monnieri (CDRI 08) on multitasking stress reactivity and mood. Phytother. Res. PTR 2014, 28, 551–559.
  11. Stough, C.; Lloyd, J.; Clarke, J.; Downey, L.A.; Hutchison, C.W.; Rodgers, T.; Nathan, P.J. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology, 2001, 156, 481–484.
  12. Morgan, A.; Stevens, J. Does Bacopa monnieri improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial. J. Altern. Complement. Med. 2010, 16, 753–759.
  13. Raghav, S.; Singh, H.; Dalal, J.S. Randomized controlled trial of standardized Bacopa monniera extract in age-associated memory impairment. Indian J. Psychiatry 2006, 48, 238–242.
  14. Barbhaiya, H.C.; Desai, R.P.; Saxena, V.S.; Pravina, K.; Wasim, P.; Geetharani, P.; Allan, J.J.; Venkateshwarlu, K.; Amit, A. Efficacy and tolerability of bacomind® on memory improvement in elderly participants—A double blind placebo controlled study. J. Pharmacol. Toxicol. 2008, 3, 425–434.
  15. Kean, J.D.; Downey, L.A.; Stough, C. A systematic review of the ayurvedic medicinal herb Bacopa monnieri in child and adolescent populations. Complement. Ther. Med. 2016, 29, 56–62.
  16. Downey, LA Kean, J et al. An acute, double-blind, placebo-controlled crossover study of 320 mg and 640 mg doses of a special extract of Bacopa monnieri (CDRI 08) on sustained cognitive performance. Phytother. Res. 2013, 27, 1407–1413.
  17. Dave, U.; Chauvan, V.; Dalvi, J. Evaluation of BR-16a (Mentat) in cognitive and behavioural dysfunction of mentally retarded children a placebo-controlled study. Indian J. Pediatr. 1993, 60, 423–428.
  18. Stough C, Lloyd J, Clarke J, et al (2001) The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology 156:481–4
  19. Dutta, B.; Barua, T.K.; Ray, J.; Adhikari, A.; Biswas, S.; Banerjee, S.; Roy, A.; Debnath, P.K. A study of evaluation of safety and efficacy of memomet, a multi herbal formulation (memomet) in the treatment of behavioural disorder in children. Int. J. Res. Pharm. Sci. 2012, 3, 282–286.
  20. Roodenrys A, Booth D, Bulzomi A, Phipps A, Micallef C, Smoker J. Chronic effects of Brahmi (Bacopa monnieri) on human memory. Neuropsychopharmacol 2002;27:279-81.
  21. Barkley, R.A. Behavioral inhibition, sustained attention, and executive functions: Constructing a unifying theory of adhd. Psychol. Bull. 1997, 121, 65–94
  22. Ault, R.L.; Crawford, D.E.; Jeffrey, W.E. Visual scanning strategies of reflective, impulsive, fast-accurate, and slow-inaccurate children on the matching familiar figures test. Child Dev. 1972, 43, 1412–1417
  23. Connor A. Emdin, et al. Blood Pressure and Risk of Vascular Dementia. Stroke, 2016; STROKEAHA.116.012658 DOI: 10.1161/STROKEAHA.116.012658
  24. Lenore J. Launer et al. Joint effect of mid- and late-life blood pressure on the brain. Neurology, June 2014 DOI: 10.1212/WNL.0000000000000517
Order the nutrients mentioned in this article
Super Omega 3

EPA and DHA: one of the most natural, pure, powerful and stable product on the market

Coenzyme Q10

Coenzyme is an oil based supplement,with three times the bioavailability, that helps:

  • the cardiovascular system
  • the immune system
  • has powerful antioxidant properties


Regulates blood pressure naturally
ACE inhibitor

Bacopa monnieri

Improves memory acquisition and retention, increases learning capacity

Follow us
Please choose your language


Thank you for visiting our site. Before you go

Club SuperSmart
And take advantage
of exclusive benefits:
  • Free: our weekly science-based newsletter "Nutranews"
  • Special offers for club members only
> Continue